Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
You may also be interested in...
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.
AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.
It’s not quite the rebate rule, but final reg aims for ‘a reduction in the use of rebates and other price concessions’ driven by the transparency requirement and broad definitions. PCMA warns that ‘mandating an increased level of disclosure for this information could result in higher prescription drug prices for consumers.’